US › Healthcare

Stoke Therapeutics Inc (STOK)

US · Healthcare · Biotechnology

$31.67+7.14%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$6.2M
Revenue YoY
-96.1%
Net profit
$-50.0M
Profit YoY
-144.3%
EPS
$-0.79
EPS estimate
$-0.82
Net margin
-802.7%

EPS came in at -0.79 against a street estimate of -0.82 — a beat of 3.7%.

Key statistics

Market cap
$1.80B
Forward P/E
204.1
P/B
4.55
Book value
$6.34
EPS (TTM)
$-2.86
52-week high
$40.22
52-week low
$12.72
50-day MA
$30.31
200-day MA
$31.66
Beta
1.18

Analyst view

Analysts rate Stoke Therapeutics Inc a strong buy (9 buy, 1 hold, 0 sell out of 10) with an average price target of $45.82.

Shareholding

Insiders
3.82%
Institutions
120.24%

Largest institutional holders

FundStake
RTW INVESTMENTS, LLC9.03%
BlackRock Inc8.65%
FMR Inc8.64%
Lynx1 Capital Management, LP7.65%
Redmile Group, LLC6.69%
Morgan Stanley - Brokerage Accounts5.50%
Baker Bros Advisors LP5.36%
The Toronto-Dominion Bank5.09%

Recent filings & reports

DocumentDate
Reg FD disclosure · Q2 20262026-06-30
Shareholder vote results · Q2 20262026-06-04
Results announced · Q2 20262026-05-07
Quarterly report · Q1 20262026-05-07
Proxy statement · Q2 20262026-04-22
Board / officer change · Q2 20262026-04-07
Annual report FY20252026-03-16
Quarterly report · Q3 20252025-11-04

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Stoke Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.